|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 41.39 USD | +0.78% |
|
-6.72% | +24.29% |
| Dec. 11 | Exelixis, Inc. - Special Call | |
| Nov. 25 | Exelixis Insider Sold Shares Worth $3,046,928, According to a Recent SEC Filing | MT |
Business description: Exelixis, Inc.
Number of employees: 1,147
Sales by Activity: Exelixis, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
Biotechnology | 988M | 1.43B | 1.61B | 1.83B | 2.17B |
Geographical breakdown of sales: Exelixis, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
United States (U.S.) | 753M | 1.09B | 1.41B | 1.65B | 1.82B |
Europe | 152M | 302M | 169M | 145M | 319M |
Japan | 83.02M | 43.5M | 28.73M | 39.49M | 27.08M |
Executive Committee: Exelixis, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2010-07-21 | |
| Director of Finance/CFO | 57 | 2015-07-14 | |
Dana Aftab
COO | Chief Operating Officer | 62 | 2016-01-31 |
Susan T. Hubbard
IRC | Investor Relations Contact | - | 2016-11-30 |
Brenda Hefti
LAW | General Counsel | - | 2025-11-06 |
Composition of the Board of Directors: Exelixis, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 2004-01-31 | |
George Poste
BRD | Director/Board Member | 81 | 2004-07-31 |
| Chairman | 76 | 1997-12-31 | |
| Director/Board Member | 64 | 2010-07-21 | |
Julie Smith
BRD | Director/Board Member | 54 | 2016-09-21 |
Maria Freire
BRD | Director/Board Member | 70 | 2018-04-04 |
Tomas Jan Heyman
BRD | Director/Board Member | 69 | 2023-05-30 |
David Johnson
BRD | Director/Board Member | 42 | 2023-05-30 |
Robert Oliver
BRD | Director/Board Member | 66 | 2023-05-30 |
Mary Beckerle
BRD | Director/Board Member | 70 | 2024-01-04 |
Company details: Exelixis, Inc.
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.78% | -6.72% | +16.85% | +162.46% | 11.06B | |
| -1.74% | -4.47% | +30.44% | +104.87% | 54.9B | |
| +2.84% | -4.78% | +163.13% | +957.64% | 40.49B | |
| +0.70% | +4.25% | +61.90% | +16.75% | 39.05B | |
| +0.28% | 0.00% | -19.56% | -43.63% | 23.02B | |
| +2.74% | -0.78% | +33.20% | -36.30% | 19.13B | |
| -0.36% | +2.27% | +83.70% | -35.66% | 17.81B | |
| +0.28% | -4.36% | -4.16% | +358.93% | 13.83B | |
| +2.90% | -2.66% | +83.31% | +200.87% | 13.83B | |
| +3.41% | -2.54% | +86.37% | +753.88% | 12.55B | |
| Average | +1.18% | -1.31% | +53.52% | +243.98% | 24.57B | |
| Weighted average by Cap. | +0.79% | -1.46% | +59.97% | +251.76% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- EXEL Stock
- Company Exelixis, Inc.
Select your edition
All financial news and data tailored to specific country editions
